Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bodewell Calming Cream is a topical over-the-counter (OTC) skin protectant formulated for the management of atopic dermatitis (eczema). Developed by P&G Ventures, a division of Procter & Gamble, the product is designed to relieve minor skin irritation and itching associated with eczema. Its primary active ingredient is colloidal oatmeal (1%), which acts as a skin protectant by forming a physical barrier and providing anti-inflammatory properties. The formulation also includes a proprietary botanical complex, often referred to as BW24, which is intended to soothe the skin and support the skin barrier. The cream has been evaluated in investigator-initiated clinical trials, including studies at the University of Alabama at Birmingham, to assess its efficacy and tolerability in adults with mild-to-moderate chronic atopic dermatitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bodewell Calming Cream.